VB13S1 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
13Multiple sclerosis/Neuromyelitis optica1

13. Multiple sclerosis/Neuromyelitis optica


Clinical trials : 3,340 Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2006-003384-30-SK
(EUCTR)
26/02/200708/11/2006A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple SclerosisA Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple Sclerosis Multiple SclerosisProduct Name: NeuroVax 300ug/mL Dose for IM Injection
Product Code: IR902
Other descriptive name: VB6S5
Other descriptive name: VB13S1
Other descriptive name: VB5S2
The Immune Response CorporationNULLNot RecruitingFemale: yes
Male: yes
200Phase 2Slovakia